Andere Kunden interessierten sich auch für
![Prevalence of PTB among patients presenting with cough of any duration]( "Prevalence of PTB among patients presenting with cough of any duration")
Prevalence of PTB among patients presenting with cough of any duration26,99 €![Behavioral Symptoms in Patients with Major Neurocognitive Disorder]( "Behavioral Symptoms in Patients with Major Neurocognitive Disorder")
Behavioral Symptoms in Patients with Major Neurocognitive Disorder32,99 €![LOW MALARIA PARASITAEMIA AMONG HIV PATIENTS IN YAOUNDE, CAMEROON]( "LOW MALARIA PARASITAEMIA AMONG HIV PATIENTS IN YAOUNDE, CAMEROON")
LOW MALARIA PARASITAEMIA AMONG HIV PATIENTS IN YAOUNDE, CAMEROON39,99 €![The Adverse Effects of Chemotherapy among children with Cancer]( "The Adverse Effects of Chemotherapy among children with Cancer")
The Adverse Effects of Chemotherapy among children with Cancer45,99 €![Quitting Smoking: More Than an Addiction for People with Diabetes]( "Quitting Smoking: More Than an Addiction for People with Diabetes")
Quitting Smoking: More Than an Addiction for People with Diabetes36,99 €![HIPEC vs EPIC in patients of Peritoneal Surface Malignancies]( "HIPEC vs EPIC in patients of Peritoneal Surface Malignancies")
HIPEC vs EPIC in patients of Peritoneal Surface Malignancies39,99 €![Surveillance thérapeutique de la clozapine chez les patients atteints de schizophrénie]( "Surveillance thérapeutique de la clozapine chez les patients atteints de schizophrénie")
Surveillance thérapeutique de la clozapine chez les patients atteints de schizophrénie26,99 €
The antipsychotic effect of clozapine, synthesized in 1959, was demonstrated in 1966. After the occurrence of an epidemic of agranulocytosis in 1976, clozapine was withdrawn from the market only to be authorized in 1991 in France. In Tunisia, clozapine began to be marketed in the late 1990s. However, its prescription remains limited despite it remaining the reference molecule for the treatment of resistant schizophrenia.Rigorous therapeutic monitoring makes it possible to monitor the appearance of adverse effects. The objective of the study is to evaluate the clinical, biological and pharmacological follow-up methods of patients treated with clozapine in relation to international recommendations and to study the correlation between the plasma levels of clozapine and clinical psychotic signs.